Germany's Merck KGaA has agreed to acquire Bio-Techne, a US maker of life-science research tools, in an all-cash deal valuing the company at about $11.3 billion, the latest in a string of acquisitions through which the Darmstadt-based group has reshaped its life-sciences business. The transaction ranks among the larger healthcare deals of the year and sent the target's shares sharply higher.
Under the agreement announced on Thursday, Merck KGaA will pay $73 per share in cash for Bio-Techne, implying a total enterprise value of roughly $11.3 billion, or about €9.9 billion. The price represents a premium of around 36% to the target's average trading price over the prior month. Bio-Techne's shares jumped more than 20% in US premarket trading toward the offer level, while Merck's stock slipped in Frankfurt, a common pattern as investors weigh the cost of a sizeable acquisition against its strategic logic.
Bio-Techne, based in Minneapolis and listed under the ticker TECH, is not a drugmaker but a supplier of the tools that laboratories and pharmaceutical companies rely on, including research reagents, proteins, antibodies, analytical instruments and bioprocessing equipment. Its products span the scientific workflow from early-stage discovery through development, testing and commercial manufacturing, with annual sales of roughly $1.2 billion. The appeal for an acquirer lies partly in the stickiness of that business: once a particular reagent or instrument is validated and written into a lab's standard process, switching suppliers tends to be slow and costly, which supports recurring orders and steadier revenue.
Merck framed the deal as a way to strengthen its position across the full life-science value chain, adding complementary capabilities in research, bioprocessing and advanced therapies. The company said the acquisition is expected to be immediately accretive to its sales growth and a key profitability measure after closing, and to begin adding to earnings within a few years. It plans to fund the purchase through a combination of existing cash and new debt while maintaining its investment-grade credit rating.
The transaction fits a familiar playbook for the German group, which has been steadily building out its tools-and-services arm through acquisitions rather than betting solely on the binary outcomes of drug development, where a single trial result or patent expiry can swing expectations sharply. By tilting its earnings mix toward consumables and manufacturing-support products, the company is aiming for a more predictable revenue profile, the kind that can influence how much volatility investors expect and the valuation they are willing to assign.
It is worth noting that Merck KGaA of Germany is a separate company from the US pharmaceutical group that operates under the Merck name in North America, a long-standing distinction that often causes confusion. The German company traces its roots to Darmstadt and operates across healthcare, life science and electronics.
The deal remains subject to approval by Bio-Techne shareholders and to clearance from regulators, but the companies said they expect it to close in the near term. If completed, it would mark another step in a wave of consolidation among suppliers of the picks-and-shovels of modern biology, as larger players move to assemble integrated portfolios that serve drug developers from the laboratory bench through to manufacturing.